Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2017 August;69(4) > Minerva Urologica e Nefrologica 2017 August;69(4):349-58

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Urologica e Nefrologica 2017 August;69(4):349-58

DOI: 10.23736/S0393-2249.16.02746-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer

Valentina BERTAGLIA 1, Marcello TUCCI 1 , Francesca VIGNANI 1, Consuelo BUTTIGLIERO 1, Emiliano AROASIO 2, Alfredo BERRUTI 3, Giorgio V. SCAGLIOTTI 1, Massimo DI MAIO 4

1 Department of Medical Oncology, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Turin, Italy; 2 Department of Biological and Clinical Sciences, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Turin, Italy; 3 Medical Oncology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy; 4 SCDU Oncologia, Mauriziano Hospital, Turin, Italy


PDF


BACKGROUND: Abiraterone acetate, approved for patients with metastatic castration-resistant prostate cancer (mCRPC), blocks androgen byosinthesis. We aimed to describe changes determined by abiraterone in hormones implied in steroid biosynthesis, exploring association between hormonal levels and drug activity.
METHODS: Patients with mCRPC, receiving standard abiraterone + prednisone after docetaxel failure, were studied. We determined serum levels of progesterone, 17OH-progesterone, cortisol, ACTH, DHEA-sulphate, androstenedione, testosterone, sex hormone-binding globulin, aldosterone, plasma renin activity, and cholesterol, baseline and every 12 weeks. For each hormone, association with treatment activity was tested 1) comparing baseline values in responders vs. non-responders; 2) comparing progression-free survival (PFS) of patients with baseline low vs. high values; 3) comparing values after 12 weeks in responders vs. non-responders.
RESULTS: Forty-nine patients were analyzed; 26 patients (53.1%) experienced PSA response. Baseline values of all hormones were not statistically different between responders and non-responders. For all hormones, PFS difference of patients with low vs. high baseline values was not statistically significant. Several hormones showed significant and sustained changes vs. baseline, but all significant changes were similar between responders and non-responders.
CONCLUSIONS: This analysis does not suggest a significant association between baseline hormonal values, or changes induced by abiraterone, and treatment activity.


KEY WORDS: Abiraterone acetate - Biological markers - Prognosis - Prostatic neoplasms

inizio pagina